Literature DB >> 24623872

Dolutegravir.

Dennis J Cada1, Terri L Levien2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The February 2014 monograph topics are sofosbuvir, simeprevir capsules, ibrutinib, hydrocodone extended-release capsules, and eslicarbazepine. The DUE/MUE is on sofosbuvir.

Entities:  

Year:  2014        PMID： 24623872      PMCID： PMC3940684          DOI： 10.1310/hpj4902-184

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  25 in total

1.  Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

Authors:  Parul Patel; Ivy Song; Julie Borland; Apurva Patel; Yu Lou; Shuguang Chen; Toshihiro Wajima; Amanda Peppercorn; Sherene S Min; Stephen C Piscitelli
Journal:  J Antimicrob Chemother       Date:  2011-04-14       Impact factor: 5.790

2.  Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

Authors:  Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; Benjamin Young; Jürgen K Rockstroh; Steve Almond; Ivy Song; Cindy Brothers; Sherene Min
Journal:  Lancet Infect Dis       Date:  2011-10-20       Impact factor: 25.071

3.  Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

Authors:  Filippo Canducci; Elisa R Ceresola; Enzo Boeri; Vincenzo Spagnuolo; Francesca Cossarini; Antonella Castagna; Adriano Lazzarin; Massimo Clementi
Journal:  J Infect Dis       Date:  2011-10-07       Impact factor: 5.226

4.  Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

Authors:  Ivy Song; Julie Borland; Shuguang Chen; Yu Lou; Amanda Peppercorn; Toshihiro Wajima; Sherene Min; Stephen C Piscitelli
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

5.  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.

Authors:  Sherene Min; Louis Sloan; Edwin DeJesus; Trevor Hawkins; Lewis McCurdy; Ivy Song; Richard Stroder; Shuguang Chen; Mark Underwood; Tamio Fujiwara; Stephen Piscitelli; Jay Lalezari
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

6.  The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.

Authors:  Mark R Underwood; Brian A Johns; Akihiko Sato; Jeffrey N Martin; Steven G Deeks; Tamio Fujiwara
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

7.  Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.

Authors:  F Saladini; G Meini; C Bianco; L Monno; G Punzi; M Pecorari; V Borghi; M Di Pietro; G Filice; M R Gismondo; V Micheli; G Penco; T Carli; A De Luca; M Zazzi
Journal:  Clin Microbiol Infect       Date:  2012-06-21       Impact factor: 8.067

8.  Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Authors:  Kelly E Dooley; Patrick Sayre; Julie Borland; Elizabeth Purdy; Shuguang Chen; Ivy Song; Amanda Peppercorn; Stephanie Everts; Stephen Piscitelli; Charles Flexner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

9.  Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.

Authors:  Stephen Castellino; Lee Moss; David Wagner; Julie Borland; Ivy Song; Shuguang Chen; Yu Lou; Sherene S Min; Igor Goljer; Amanda Culp; Stephen C Piscitelli; Paul M Savina
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

10.  Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

Authors:  Hans-Jürgen Stellbrink; Jacques Reynes; Adriano Lazzarin; Eugene Voronin; Federico Pulido; Franco Felizarta; Steve Almond; Marty St Clair; Nancy Flack; Sherene Min
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177
View more
  1 in total

Review 1.  Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review.

Authors:  N Wagner; C A Wyler-Lazarevic; S Yerly; C Samer; G Peytavin; K M Posfay-Barbe; A Calmy; J Ambrosioni
Journal:  New Microbes New Infect       Date:  2015-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.